The Illinois Municipal Retirement Fund increased its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 3.0% in the fourth quarter, according to its latest SEC filing. The institutional investor owned his 420,275 shares of the biopharmaceutical company’s stock after purchasing an additional 12,184 shares during the quarter. Bristol-Myers Squibb represents approximately 0.7% of the Illinois Municipal Retirement Fund’s investment portfolio and is the 16th largest holding. Illinois Municipal Retirement Fund holdings in Bristol-Myers Squibb were valued at $30,239,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares in the company. Ignite Planners LLC increased his Bristol-Myers Squibb holding by 5.8% in the fourth quarter. Ignite Planners LLC now owns 7,099 shares of the biopharmaceutical company valued at $516,000 after acquiring an additional 387 shares during this period. Cornerstone Retirement Group Inc. purchased a new position in Bristol-Myers Squibb in the fourth quarter for approximately $242,000. Deuterium Capital Management LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter for approximately $271,000. Securian Asset Management Inc. increased his stake in Bristol-Myers Squibb by 3.3% in the fourth quarter. Securian Asset Management Inc. now owns 179,741 shares of the biopharmaceutical company worth $12,932,000 after purchasing an additional 5,749 shares of him last quarter. Finally, Curi Wealth Management LLC purchased a new position in Bristol-Myers Squibb stock for approximately $300,000 in the fourth quarter. Institutional investors and hedge funds own 75.51% of the company’s shares.
In other news, CEO Giovanni Caforio sold 240,000 shares in the company in a deal on Monday, February 6th. The shares sold for an average of $74.65, and the total transaction value he had was $17,916,000.00. Following the closing of the sale, the CEO now directly owns 236,104 shares of the Company’s stock valued at $17,625,163.60. The sale is disclosed in documents filed with the SEC and available on his website. In separate news, EVP Ann Powell sold 11,183 shares of the company’s stock in her Monday, Feb. 6 transaction. The shares sold for an average of $74.69, with a total trading value of $835,258.27 for her. Following the closing of the sale, the Executive Vice President now owns 23,043 shares of the company directly, valued at approximately $1,721,081.67. The deal is disclosed in documents filed with the Securities and Exchange Commission and can be accessed on her website at the SEC. CEO Giovanni Caforio also sold 240,000 shares of the company in a deal on Monday, February 6th. The shares sold for an average of $74.65, giving him a total of $17,916,000.00. After the sale, the CEO now directly owns 236,104 shares of the company stock valued at $17,625,163.60. Please see here for the disclosure of this sale. His 0.09% of the shares are now owned by insiders.
Bristol-Myers Squibb Price Performance
NYSE:BMY shares rose $0.82 on Friday to reach $70.35. His 2,688,099 shares of the company traded, with an average trading volume of 7,838,006 of his shares. The company has a debt to equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14. The stock has a market capitalization of $147.97 billion, a PE ratio of 23.57, a P/E/G ratio of 1.54, and a beta of 0.45. The company has a 50-day moving average of $69.27 and a 200-day moving average of $72.73. His 52-week low for Bristol-Myers Squibb is $65.28 and his 52-week high is $81.43.
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last reported earnings on Thursday, February 2nd. The biopharmaceutical company reported EPS of $1.82 for the quarter, beating consensus expectations of $1.71 by $0.11. Bristol-Myers Squibb had a return on equity of 51.60% and a net profit margin of 13.71%. The business generated revenue of $11.41 billion during the quarter, compared to consensus expectations of $11.2 billion. Earnings of $1.83 per share last year. Bristol-Myers Squibb revenues decreased 4.8% compared to the same quarter last year. As a group, analysts expect Bristol-Myers Squibb to post his 8.07 earnings per share for the current financial year.
Bristol-Myers Squibb Dividend Announcement
The company recently announced a quarterly dividend payable on Monday, May 1st. Dividends of $0.57 per share will be issued to shareholders of record on Monday, April 10. This represents his $2.28 dividend and his 3.24% dividend yield on an annualized basis. The ex-dividend date is Thursday, April 6. Bristol-Myers Squibb has a payout ratio of 77.29%.
Analyst upgrades and downgrades
BMY has been the subject of several research analyst reports. Atlantic Securities raised its price target on Bristol-Myers Squibb from $88.00 to $90.00, giving the company an “overweight” rating in its research notes on Friday, February 3. Wells Fargo & Company raised its price target on Bristol-Myers Squibb from $70.00 to $78.00 and gave it an “equal weight” rating in its research notes on Tuesday, January 3. Morgan Stanley raised its price target on Bristol-Myers Squibb from $60.00 to $62.00, giving it an “underweight” rating in its research notes on Friday, February 3rd. Bank of America raised its price target for Bristol-Myers Squibb from $82.00 to $85.00 in a research note on Friday. Finally, StockNews.com in his Thursday, March 16 investigative notes he assumed coverage of Bristol-Myers Squibb. They assigned a “strong buy” rating to the stock. One equity research analyst gave the stock a sell rating, seven assigned a hold rating, seven gave a buy rating, and a A person gave the stock a strong buy rating. According to MarketBeat.com, the company’s current average rating is “moderate buy” with an average target price of $80.00.
Bristol-Myers Squibb Company Profile
Bristol Myers Squibb Co is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals. We offer chemically synthesized drugs and small molecules, as well as products derived from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, New York.
Want to know which other hedge funds hold BMY? Visit HoldingsChannel.com for the latest Bristol-Myers Squibb (NYSE:BMY – Get Rating) 13F filings and insider trading.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to firstname.lastname@example.org.
Listen to this before considering the Bristol-Myers Squibb.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Bristol-Myers Squibb is not on the list was.
Bristol-Myers Squibb currently has a “Hold” rating among analysts, but the highest rated analysts believe these five stocks are better buys.
See 5 stocks here